chemotherapy. Conclusion: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy.
Introduction
Angiosarcomas (AS) are rare malignant endothelial cell tumors of vascular origin which account for <2-3% of all soft tissue sarcomas [1] . As a disease state, AS have highly heterogeneous patterns of presentation and clinical courses [2, 3] . AS occur with similar incidence amongst both sexes and are generally more common in the 6th and 7th decades of life [3, 4] . Despite its ubiquitous anatomic presentation, the most frequent primary sites include the skin of the head/neck, breast and deep soft tissues. Less frequently, AS arise in visceral organs, bone and retroperitoneum [4] [5] [6] [7] . The clinical course and response to treatment may vary depending on the primary location, and some series have suggested longer survival and higher response rates for cutaneous AS arising in the face and scalp [8] [9] [10] , although this observation was not uniform [11, 12] . While only 3% of AS can be attributable to a documented predisposing syndrome (Recklinghausen's disease, Ollier's disease, etc.) [3, 4, 13] , several factors have been associated with an increased risk of developing AS, including chronic lymphedema (Stewart-Treves syndrome), prior exposure to ionizing radiation and exogenous toxins, including thorium dioxide (Thorotrast), polyvinyl chloride and arsenical insecticide [3, 4, 6, 14, 15] . Histologically, AS are characterized by spindled, polygonal, epithelioid and primitive round cells interspersed with endothelial cells, with expression of both vascular and endothelial antigens on immunohistochemistry, including factor-VIII, CD31, CD34 and VEGF [4, 5, 16] .
Surgical resection remains the cornerstone of treatment for patients with localized disease. While additional benefit can potentially be derived from adjuvant radiotherapy when indicated, this strategy has never demonstrated a proven survival benefit [16] . Overall, the survival rates 5 years after diagnosis are approximately 30-35% [16, 17] . Poor prognostic factors at diagnosis, although not uniform across different series, include large tumor size (>5 cm), primary site (liver, heart and retroperitoneal disease), radiation-associated AS, deep primary tumor, high mitotic count, margin status, older age, poor performance status and presence of metastases at diagnosis [6, 7, [18] [19] [20] [21] [22] .
Despite adequate locoregional treatment, almost half of the patients initially treated with curative surgical intent will ultimately develop metastatic disease and up to 20-40% of the patients have disseminated disease at initial presentation [4, 18, 19] . For patients with metastatic disease, the median overall survival (mOS) is approximately 8-14 months [4, 6] .
Activity of a number of agents has been reported in the metastatic setting, including anthracyclines, taxanes, dacarbazine, gemcitabine and angiogenesis inhibitors, with response rates ranging from 10 to 60% [8] [9] [10] [11] [23] [24] [25] [26] [27] [28] [29] . While prospective clinical trials limited to patients with AS have been conducted, these are limited in number and sample size and were, with rare exceptions, nonrandomized. Hence, most of the data used for treatment decisions result from retrospective series [8, 10, 11, [23] [24] [25] [26] [27] [28] [29] .
Although some results suggest higher response rates of cutaneous AS to taxanes, particularly those originating in the head and neck/scalp [8, 9] , other agents have also been shown to be active in different scenarios. Overall, the impact on survival of choice of treatment based on histologic features and site of origin is unclear [23, 24] . Controversy exists regarding the optimal first-line treatment and whether different approaches should be tailored to the diverse subgroups. In addition, there is limited information regarding the results of subsequent lines of treatment and the outcomes of different agents used sequentially and in different orders for patients with advanced AS.
In this analysis, we sought to evaluate patients with metastatic AS treated at a single institution specifically with regard to outcomes and the efficacy of systemic treatment.
Materials and Methods

Study Design and Population
Using our institutional sarcoma database and data query system, patients with AS who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between 1987 and 2012 were identified. Eligible patients were required to have a centrally reviewed, histologically confirmed diagnosis of advanced or metastatic AS. Following approval by the Institutional Review Board, relevant information was retrieved from electronic medical records including: gender, age at the time of diagnosis, Karnofsky Performance Status (KPS) scale, features at presentation (localized vs. advanced disease), primary tumor characteristics (location, size, etc.), prior radiation exposure, presence of pulmonary and extrapulmonary visceral metastases, presence of bone metastases, treatment-related variables (type of chemotherapy, duration, number of systemic treatment lines) as well as survival dates, including progression dates for each individual treatment line. Primary sites were divided into 6 categories (head/neck, trunk/breast, extremities, retroperitoneum, visceral and other) based on the classification proposed by Brennan et al. [30] and used in the prospectively maintained database. The largest dimension of the primary tumor determined pathologically defined tumor size; it was also stratified as ≤ 5, 5.1-10 or >10 cm. KPS was stratified as <80% or ≥ 80%. Grade was not evaluated because all AS are considered to be highgrade tumors, with the exception of a small proportion of patients with primary breast AS [21] .
For patients with target lesions, radiologic evaluation was performed at baseline and every 2-3 cycles of systemic therapy and reviewed for the purpose of this analysis by a reference radiologist (J.L.). Partial and complete radiologic responses were determined retrospectively according to the Response Evaluation Criteria in Solid Tumors -RECIST v1.1 for those patients whose images could be retrieved.
Since the toxicity profile of treatment regimens used for metastatic AS is well described in the literature, details on adverse events were not pursued.
Statistical Considerations
Patients' characteristics are presented by frequencies and percentages for categorical variables and median and range for continuous variables. was estimated from date of first systemic treatment for metastatic disease to date of death from any cause or last follow-up. Univariate analysis was performed for factors influencing TTP and OS. Fisher's test was used to assess the relationship between response to first-line treatment and patients' characteristics. Variables that were significant in the univariate setting were added to the multivariate model. Survival curves were estimated using the KaplanMeier method. p values <0.05 were considered significant. All analysis was done using R version 3.1.1.
Results
Demographics and Disease Characteristics
We identified 119 patients with metastatic AS treated at MSKCC between 1987 and 2012 ( table 1 ). There was a slight female preponderance (female/male ratio: 1.4; female 58%, male 42%). The primary tumor size at the time of diagnosis was ≤ 5 cm in 43 (36%), 5.1-10 cm in 33 (28%) and >10 cm in 22 patients (18%). Size description was missing or unknown in 21 patients (18%). Median age was 61 years, ranging from 19 to 86 years. KPS at the start of chemotherapy was 80-100% for 54 patients (45%), <80% for 18 patients (15%) and missing for 47 patients (40%). Metastatic AS most frequently originated in the trunk (n = 37, 31%; 31 primary breast and 6 chest wall), followed by viscera (n = 26, 22%) and head/neck (n = 24, 20%). Overall, 33 (28%) were classified as cutaneous AS originating in the head/neck (n = 22), extremities (n = 9) and other/unknown (n = 2), while 8 (7%) arose from bone. In this analysis, there were 28 patients (24%) that developed AS in a previously irradiated area including the breast (n = 21), chest wall (n = 2), extremities (n = 2) and liver/neck/retroperitoneum (n = 1 each). Extrapulmonary visceral involvement occurred in 45 patients (38%) and osseous metastases in 33 (28%).
Treatment Details
Most frequently used agents across different lines included doxorubicin (single agent or in combination with ifosfamide), paclitaxel, liposomal doxorubicin and tyrosine kinase inhibitors (TKI) sunitinib and sorafenib. Pazopanib was not in use at the time these patients were treated. Other treatments included gemcitabine, vinorelbine, everolimus and miscellaneous (platinum agents, dacarbazine, temozolomide, brivanib and bevacizumab). Overall, 73 patients (61%) received 2 or more lines of chemotherapy, and 46 (39%) received at least 3 lines of treatment. The median number of lines of therapy was 2, and 3 patients received up to 7 lines of treatment. Strategies for locoregional control, including radiation therapy, ablative procedures and surgical resections were not used concurrently with systemic treatments.
Most patients were treated with anthracyclines (doxorubicin-based or liposomal doxorubicin; n = 74, 62%) and taxanes (n = 74, 62%) at some point during their treatments ( table 2 ) . Overall, 49 patients (41%) received anthracyclines in the first-line setting. There were 28 (24%) patients that received doxorubicin-based regimens either as a single agent (n = 8) or in combination with ifosfamide or dacarbazine (n = 20). In addition, 21 (18%) patients received liposomal doxorubicin. Taxanes (paclitaxel single agent: 41, paclitaxel combination: 1, docetaxel combination: 3) were the initial treatment in 45 (38%) cases. Sorafenib or sunitinib were recommended for 9 patients (8%) in first line. Following progression, 73 patients received secondline therapies that included anthracyclines (n = 21, 29%), taxanes (n = 24, 33%), sorafenib/sunitinib (n = 7, 10%) or other drugs (n = 21, 29%). Among the 46 patients that received a third line of treatment, 13 (28%) received gemcitabine.
In general, a similar number of patients received 2 or more lines of treatment after progressing on first-line anthracyclines (n = 30; 61%) in comparison to first-line taxanes (n = 27; 60%). There were 16 (36%) patients that received first-line taxanes who crossed over to anthracyclines anytime during treatment. Similarly, 20 (41%) pa- 
Overall Survival
At the time of the analyses, 106 patients had died, and mOS was 12.1 months (online suppl. fig. 1 ; see www. karger.com/doi/10.1159/000381917 for all online suppl. material). Nine patients were still alive, including 5 without evidence of disease as a result of complete response to chemotherapy or additional surgical resection of sites of metastases. Median follow-up amongst survivors was 93.8 months.
In univariate analysis, larger primary tumor size (>10 cm; p = 0.003), KPS at first chemotherapy ≤ 70% (p = 0.049) and presence of visceral involvement (p = 0.041) were significantly associated with shorter OS ( fig. 1 ) . In multivariate analysis, large primary tumor size (>10 cm; p = 0.014) was confirmed as a poor independent prognostic factor of decreased OS. Due to the large number of patients for whom KPS status was missing (n = 47, 40%), this variable was excluded from the multivariate analysis.
Cutaneous AS had a similar mOS versus noncutaneous AS (15.3 vs. 10.9 months; p = 0.498; fig. 1 ). There was no difference in OS observed between patients with AS arising in previously irradiated areas versus other AS (10. fig. 1 ). Similarly, patients treated with combination chemotherapy had similar OS to those treated with single agents in first line (p = 0.789 for any single agent vs. any combination).
Time to Tumor Progression
The median TTP (mTTP) was 3.5 months in the firstline, 3.7 months in the second-line and 2.7 months in the third-line setting. In a univariate analysis, only the presence of visceral involvement predicted a shorter progression-free interval to first-line therapy (p = 0.019). No statistically significant differences in firstline mTTP were observed between anthracyclines (single agent or combination -mTTP 3.4 months), taxanes (single agent or combination -mTTP 3.6 months) and other agents (mTTP 3.0 months; p = 0.48) in the firstline setting. Of note, mTTP for liposomal doxorubicin was 3.9 months. The choice of single agent versus combination had no impact on mTTP either (p = 0.498; fig. 2 ; see table 4).
Response to Treatment
Of the 119 patients identified, 48 were radiographically evaluable for response based on RECIST v1.1 ( table 3 ). One patient was not evaluable for first line due to inadequate baseline scans. Overall response rate (ORR) to first-line therapy was 30% (n = 14), and 19 patients (40%) achieved stable disease as best response ( fig. 2 b) ; 14 patients (30%) had progression of disease at first response assessment.
Objective responses to second and third lines occurred in less than 10% of the patients, and 1 patient had significant response after treatment with combination chemotherapy in fourth line. In the second-and third-line settings, 42 and 27% had stable disease as best response, respectively. The rates of stable disease were 25 and 20% in fourth and fifth lines, respectively. No objective responses were documented in lines 5-7.
We could not identify any factors predictive of response. Response rate was not significantly influenced by the type of first-line therapy (ORR: 25% for doxorubicinbased, 33% for liposomal doxorubicin, 31% for taxanes; p = 1.00). Patients receiving anthracyclines and taxanes in combinations achieved an ORR of 43% in comparison to 28% for the same agents in monotherapy (p = 0.41). Response rates in patients with cutaneous AS were 50% compared to 24% in the noncutaneous group (p = 0.196; table 4 ). 
Discussion
AS are rare malignancies associated with a high risk of relapse, representing a life-threatening condition when diagnosed at advanced stages [4, 6] . Although anthracyclines, taxanes, gemcitabine and TKI are frequently recommended for patients with metastatic disease [8, 11, [23] [24] [25] [26] [27] [28] , there are limited data guiding the ideal sequence of each of these agents. Furthermore, the benefit of systemic therapy for those who progress after first line is unclear. Here, we present the results of one of the largest retrospective series of patients with metastatic AS and the first to evaluate the details of management after progression on first-line chemotherapy. In this cohort of patients treated predominately with anthracyclines or taxanes, the mOS was 12.1 months; mTTP and ORR in first, second and third lines were 3.5 months and 10%, 3.7 months and 8% and 2.7 months and 9%, respectively. Although primary tumor size >10 cm, KPS ≤ 70% and presence of extrapulmonary visceral involvement were associated with shorter OS in univariate analysis, only tumor size was confirmed as a poor prognostic factor in multivariate analysis, which could reflect a more aggressive biology. The choice of chemotherapy (doxorubicin-based vs. taxane-based vs. liposomal doxorubicin) did not correlate with response rates or survival, and similar proportions of patients received both classes of drugs. Of note, the use of combination chemotherapy was not associated with improved OS when compared to the consecutive use of single-agent drugs (p = 0.463).
Baseline characteristics of patients in our analysis are concordant with earlier data, including age, female/male ratio and frequency of patients with RT-associated AS. While distribution varies across different studies, head/ neck and chest/breast are typical primary sites for AS [3, 4, 6, 19] , and an elevated proportion of visceral primary AS (22% in our series) has also been reported by others [19, 24] . Survival outcomes herein reported are in line with previously published studies ( table 5 ), in which the mTTP ranged between 1.7 and 7.6 months and mOS between 5.5 and 19.5 months. In the largest series published to date (n = 149) [24] , 46.9% of the patients received doxorubicinbased combinations; 31.5% weekly paclitaxel and 10.9% palliative care only. There was no significant difference in terms of OS between weekly paclitaxel and doxorubicinbased regimens (11.0 vs. 13.1 months; p = 0.81). In the single-arm phase II ANGIOTAX trial, weekly paclitaxel demonstrated an ORR of 19%, with an mTTP of 4 months and mOS of 8 months [27] . The same group has recently presented a phase II trial which randomized patients to receive weekly paclitaxel with or without bevacizumab. Single-agent paclitaxel resulted in a response rate of 40%, median progression-free survival (mPFS) of 6.8 months and mOS of 19.5 months. Of note, the dose of paclitaxel was slightly higher in comparison to other studies (90 vs. 75-80 mg/m 2 weekly or 175 mg/m 2 every 3 weeks in most retrospective series and the ANGIOTAX trial) [28] . Interestingly, in our series we found no correlation between history of prior radiation and either survival or response to treatment in the metastatic setting, and this confirms prior observations [19, 23, 24] , suggesting that these patients should be managed similarly to those with primary AS.
While both taxanes and anthracyclines are considered active and frequently recommended for AS patients, no randomized, controlled trials have been conducted to date comparing these two classes, and controversy still exists regarding the best treatment choice and sequence of treatment [6] . We found similar results in terms of ORR, mTTP and mOS in patients treated with doxorubicin, liposomal doxorubicin and taxanes. In a multi-institutional series that included 117 patients [23] , the response rate was significantly higher with weekly paclitaxel group in comparison to doxorubicin (53 vs. 29%; p = 0.02). However, patients treated with paclitaxel were more likely to have pri- 213 mary skin AS (89% of the patients with cutaneous AS received paclitaxel); in the subgroup of noncutaneous AS, no significant difference in terms of objective response rate between weekly paclitaxel and doxorubicin was observed (40 vs. 26%; p = 0.2) [23] . It is also important to highlight that we report the largest number of AS patients treated with liposomal doxorubicin, which resulted in an ORR of 33% and mTTP of 3.9 months in the first-line setting. Hence, liposomal doxorubicin may be a reasonable front line option for patients with metastatic AS. This is also the first series to provide more robust details regarding the management of patients beyond first line. The choice between taxanes or anthracyclines upfront did not have an impact on survival outcomes; this is likely due to the fact that patients went on to receive either drug in subsequent lines. Overall exposure to either class of drugs was similar: 62% of the patients were exposed to anthracyclines and 62% to taxanes throughout the course of their disease. Rates of crossover between anthracyclines and taxanes and vice versa were also comparable (36% from taxanes to anthracyclines and 41% from anthracyclines to taxanes). Although response rates were inferior to 10%, disease stabilization was achieved in 42% (n = 10) in the second-line and 27% (n = 3) in the third-line setting. In the series by Italiano et al. [23] , data regarding the management of patients after first-line chemotherapy were available for only 43 individuals, and only 26 received at least 2 lines of treatment. Chemotherapy regimens beyond second line were diverse, and only 3 patients out of 26 (11%) experienced a partial objective response; mPFS was 1.9 months [23] .
Results were reported by Stacchiotti et al. [11] in a retrospective analysis of 25 cases treated with single-agent gemcitabine, whereby 64% of the patients achieved objective responses and mOS was 17 months. Unfortunately, very few patients received this drug in first or second line in our series and the activity of gemcitabine could not be adequately described. In addition, only a small number of patients received TKI (8% in first line, 9% in second line). Despite its vascular origin and evidence of proangiogenic pathway activation in AS [31, 32] , results with antiangiogenic agents and TKI remain disappointing. In the largest prospective study of sorafenib in patients with soft tissue sarcomas, ORR and mPFS among 37 AS patients were 14% and 3.8 months, respectively [26] , and similar results were reported by von Mehren et al. [33] and Ray-Coquard et al. [10] (ORR of 0 and 14.6% with sorafenib, respectively). Despite some evidence of activity of bevacizumab in a single-arm phase II trial that included patients with AS and epithelioid hemangioendothelioma (four partial responses, ORR = 17%; 2 patients with AS and 2 patients with epithelioid hemangioendothelioma) [25] , there were no statistically significant differences between paclitaxel with or without bevacizumab in terms of ORR (40 vs. 50%), mPFS (6.8 vs. 6.9 months) and mOS (19.5 vs. 15.9 months) in the randomized, phase II ANGIOTAX-PLUS trial [28] .
The retrospective nature of this series poses limitations: there was high heterogeneity regarding the types of treatment beyond second line, and this limited the power of additional analyses, and the population was quite diverse; therefore, it is not possible to generalize these data. In addition, the small number of specific subsets limited analyses addressing the best chemotherapy choice for particular subtypes, such as cutaneous AS and visceral AS. Hence, although some of our observations provide basis for hypothesis generation, they do not allow us to make definitive conclusions or change clinical practice.
There remains the need to continue to identify additional molecular changes to better characterize this heterogeneous disease and determine biomarkers predictive of response to therapy in the adjuvant and metastatic setting. Already defined molecularly subsets of AS include those with MYC and/or FLT4 (VEGFR-3) alterations and KDR (VEGFR-2) mutations [32, 34] . We previously reported the efficacy of sorafenib in a small series of radiation-associated breast AS patients [35] . Complete and partial responses were seen in patients with co-amplification of MYC and FLT4 treated with sorafenib as the first-or second-line therapy. This observation highlights a strategy for better outcomes in the future: personalization of medicine based on the presence of targets of therapeutic relevance.
Conclusion
Our findings suggest that AS are chemosensitive malignancies. Despite objective responses being documented in subsequent lines of treatment, benefit from systemic therapy is short-lived, and new approaches for the management of patients with advanced disease remain an unmet need. Although the best treatment order is yet to be determined, doxorubicin, liposomal doxorubicin and taxanes resulted in similar outcomes, and should be used sequentially as single agents in most circumstances. Taxanes and liposomal doxorubicin are associated with substantial response rates and have an acceptable toxicity profile, and the choice of these drugs as preferable firstline options is reasonable. Further exploration of the molecular pathophysiology and biology to identify better targets for systemic therapy is crucial.
